Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings
DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions.
DGX Stock Gains Following the Launch of New AD-Detect Blood Test
Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.
Is Quest Diagnostics Stock Worth Holding Onto Right Now?
Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX.
DGX Stock Set to Benefit From New Google Cloud Partnership
Quest Diagnostics teams up with Google Cloud to streamline data and personalize customer experiences using gen AI.
Quest Diagnostics Stock Jumps 38% in a Year: What's Behind the Surge?
DGX outperforms the industry and the S&P 500 composite's gain in the past year, driven by strong core performance and contributions from acquisitions.
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?
DGX stays on investors' radars due to its robust prospects in Advanced Diagnostics and progress in the acquisition strategy.
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics Stock to Gain From Innovation Amid Industry Threats
Within brain health, the robust demand for AD-detect blood tests for assessing Alzheimer's disease risk drives solid growth for DGX in the fourth quarter of 2024.
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) is a Great Momentum Stock: Should You Buy?
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Quest Diagnostics Stock Was Blasting Higher Today
Quest Diagnostics (DGX 5.49%) stock was teasing its all-time high on Thursday, no mean feat for a company that's been publicly traded for decades. The healthcare testing specialist's share price was up by more than 5% in late afternoon action, well ahead of the S&P 500 index's 0.8% gain at that point in the day.
